Hyperthyroxinemia in patients receiving thyroid replacement therapy.
Eleven patients, with a history of hypothyroidism, who had hyperthyroxinemia and an elevated free thyroxine index but normal serum triiodothyronine concentrations on levothyroxine replacement underwent levothyroxine dose reduction at three-month intervals until the free thyroxine index fell into the normal range. All were clinically euthyroid throughout. Normalization of the thyrotropin response to thyrotropin-releasing hormone occurred concomitantly, indicating correction of subtle hyperthyroidism. The mean thyroxine dose decreased from 161 micrograms/d (2.06 micrograms/kg) to 120 micrograms/d (1.51 micrograms/kg). The resting heart rate fell in eight of 11 patients (P less than .02). The left ventricular ejection fraction decreased in eight of 11 patients, although the decrease was not statistically significant. Considering the sensitivity of pituitary, cardiac, and bone tissue to even a small excess of thyroxine over time, hyperthyroxinemia associated with an elevated free thyroxine index should be corrected even in patients taking levothyroxine replacement who are clinically euthyroid and whose serum triiodothyronine concentrations are within normal limits.
Grund
F M
FM
Department of Nuclear Medicine, Veterans Administration Medical Center, Minneapolis, MN 55417.
Niewoehner
C B
CB
D000328:Adult; D000368:Aged; D001835:Body Weight / Q000187:drug effects; D003404:Creatinine / Q000097:blood; D005260:Female; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D006981:Hyperthyroxinemia / Q000139:chemically induced*; D007037:Hypothyroidism / Q000188:drug therapy*; D008297:Male; D013974:Thyroxine / Q000008:administration & dosage* / Q000097:blood; D014284:Triiodothyronine / Q000097:blood
D014284:Triiodothyronine; D003404:Creatinine; D013974:Thyroxine